Evaluation of The Relationship Between Apelin 36 and Oxidative Stress In Patients With General Anxiety Disorder
Abstract
Methods: In this study, 61 patients diagnosed generalized anxiety disorder at psychiatry polyclinic and 55 control subjects were enrolled. The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and the Hamilton Anxiety Rating Scale (HARS) were used in this study and they were filled by the patients and healthy individuals. Serum apelin-36 level was measured by using an ELISA kit. Total antioxidant status (TAS) and Total Oxidant Status (TOS) in the serum was measured by an automated system. The data were analyzed by using the SPSS.
Results: It was found that serum apelin-36, TOS and Oxidative stress index (OSI) levels were significantly lower in patients’ group than controls. In addition, negative correlation was detected between apelin 36 levels and HARS scores, TOS and OSI values in patients’ group. TAS values were found as similar between the patient and control group. There was no correlation between TAS and Apelin 36 in the patient group.
Conclusion: In this study it was found that serum apelin-36, TOS and OSI levels were low in GAD. According to the results, Apelin-36 and oxidative stress may play a role in the etiopathogenesis of Generalized Anxiety Disorder.
Keywords
Apelin 36, , General Anxiety Disorder,, Oxidative stress,, Total antioxidant status,, total oxidant status
References
- 1. Stein MB. Public Health Perspectives on Generalized Anxiety Disorders. J Clin Psychiatry 2004;65: 3–7.
- 2. Pitsavos C, Panagiotakos D, Papageorgiou C, Tsetsekou E, Soldatos C, Stefanadis C. Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. Atherosclerosis 2006;185(2):320–6.
- 3. Ding L, Zhang C, Masood A, Jianxin Li, Jiao Sun et al. Protective effects of phosphodiesterase 2 inhibitor on depression and anxiety like behaviors: Involvement of antioxidant and anti-apoptotic mechanisms. Behav Brain Res 2014;268:150–8.
- 4. Mcgaugh J, Mclntyre C, Power A. Amygdala modulation of memory consolidation: İnteraction with other brain systems. Neurobiol Learn Mem 2002;78(3):539–52.
- 5. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophsy Res Commun1998;251(2):471–6. 6. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y et al. Molecular and functional characteristics of APJ: Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000;275(28):21061–21067.
- 7. Sakamoto K, Murakami Y, Sawada S, Ushikubo H, Mori A et al. Apelin-36 is protective against N-methyl-D-aspartic-acid-induced retinal ganglion cell death in the mice. Eur J Pharmacol 2016;791:213–220.
- 8. O’Donnell LA, Agrawal A, Sabnekar P, Dichter MA, Lynch KD. Apelin, an endogenous neuronal peptide, protects hippocampal neurons against excitotoxic injury. J Neurochem 2007;102(6):1905–1917.
- 9. Japp AG, Cruden NL, Amer DAB, Vivienne KY Li, Goudie EB et al. Vascular Effects of Apelin In Vivo in Man. J Am Coll Cardiol 2008;52(11):908–913.
- 10. Gu Q, Zhai L, Feng X, Chen J, Miao Z et al. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int 2013;63: 535–40.
- 11. Kutlay O. The impact of apelin-36 on isolated rat hearts as a member of apelin family Bratisl Med J 2018; 119(10): 625–9.